NLRP3 and Parkinson disease: Exendin-4 and linagliptin can be used as novel anti-inflammatory agents in PD by reducing ROS production and attenuating neuroinflammation through inhibition of NLRP3-cellular pyroptosis pathway (Yu et al., 2023).